Biosimilar developer Biocon said this week that it will share in the global profits of Hulio, an adalimumab biosimilar referencing Humira, that is licensed to Mylan by Fujifilm Kyowa Kirin Biologics.
Biosimilar developer Biocon said this week that it will share in the global profits of Hulio, an adalimumab biosimilar referencing Humira, that is licensed to Mylan by Fujifilm Kyowa Kirin Biologics.
Mylan entered into a partnership with Fujifilm Kyowa Kirin Biologics to commercialize the biosimilar in Europe in April 2018, and the European Commission authorized the product for marketing in September 2018. The next month, Mylan launched the product in Europe after having obtained a nonexclusive royalty license with Humira’s developer, AbbVie, for the use and sale of adalimumab in Europe. Through the deal, Mylan was granted a sublicense to sell the product.
In a May 7 statement, a Biocon representative said that commercialization rights to the biosimilar had been extended from Europe to the global marketplace. Under the terms of its global partnership with Mylan for monoclonal antibodies, Biocon will retain its economic interest in the biosimilar and will gain a share of profits from the global market.
While Hulio is not yet approved in the United States, in July 2018, AbbVie indicated that it had reached a settlement with Mylan that will grant the drug maker a license to sell the biosimilar in the United States beginning on July 31, 2023. Mylan will pay royalties on its sales to AbbVie.
Mylan and Biocon have partnered on other biosimilar projects to date, including a pegfilgrastim biosimilar referencing Neulasta. The biosimilar, Fulphila, has been approved in the European Union and in the United States; in the US market, the product launched at a 33% discount to the reference product, which is one of the deeper discounts achieved to date in the US biosimilar experience.
The Mylan—Biocon partnership currently has 1 additional biosimilar product approved for marketing by both the European Commission and the FDA: Ogivri, a trastuzumab biosimilar referencing Herceptin. The drug has not yet been launched in the United States.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.